KEGG   DRUG: Ixekizumab
Entry
D10071                      Drug                                   
Name
Ixekizumab (USAN);
Ixekizumab (genetical recombination) (JAN);
Taltz (TN)
Product
Sequence
(A chain)
QVQLVQSGAE VKKPGSSVKV SCKASGYSFT DYHIHWVRQA PGQGLEWMGV INPMYGTTDY
NQRFKGRVTI TADESTSTAY MELSSLRSED TAVYYCARYD YFTGTGVYWG QGTLVTVSSA
STKGPSVFPL APCSRSTSES TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG
LYSLSSVVTV PSSSLGTKTY TCNVDHKPSN TKVDKRVESK YGPPCPPCPA PEFLGGPSVF
LFPPKPKDTL MISRTPEVTC VVVDVSQEDP EVQFNWYVDG VEVHNAKTKP REEQFNSTYR
VVSVLTVLHQ DWLNGKEYKC KVSNKGLPSS IEKTISKAKG QPREPQVYTL PPSQEEMTKN
QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD GSFFLYSRLT VDKSRWQEGN
VFSCSVMHEA LHNHYTQKSL SLSLG
(B chain)
DIVMTQTPLS LSVTPGQPAS ISCRSSRSLV HSRGNTYLHW YLQKPGQSPQ LLIYKVSNRF
IGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCSQSTHLP FTFGQGTKLE IKRTVAAPSV
FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDSTYSL
SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
(Disulfide bridge: A22-A96, A133-B219, A146-A202, A225-A'225, A228-A'228, A260-A320, A366-A424, A'22-A'96, A'133-B'219, A'146-A'202, A'260-A'320, A'366-A'424, B23-B'93, B139-B199, B'23-B'93, B'139-B'199)
  Type
Peptide
Class
Immunological agent
 DG02019  Interleukin inhibitor
Remark
Therapeutic category: 3999
ATC code: L04AC13
Product: D10071<JP/US>
Efficacy
Antipsoriatic, Anti-IL-17A antibody
  Disease
Plaque psoriasis [DS:H01656]
Psoriatic arthritis [DS:H01656]
  Type
Monoclonal antibody
Comment
Treatment of autoimmune diseases
Target
IL17A [HSA:3605] [KO:K05489]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04657  IL-17 signaling pathway
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L04 IMMUNOSUPPRESSANTS
   L04A IMMUNOSUPPRESSANTS
    L04AC Interleukin inhibitors
     L04AC13 Ixekizumab
      D10071  Ixekizumab (USAN) <JP/US>
USP drug classification [BR:br08302]
 Immunological Agents
  Immunological Agents, Other
   Interleukin Blockers
    Ixekizumab
     D10071  Ixekizumab (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
 3  Agents affecting metabolism
  39  Other agents affecting metabolism
   399  Miscellaneous
    3999  Others
     D10071  Ixekizumab (USAN); Ixekizumab (genetical recombination) (JAN)
Drug groups [BR:br08330]
 Immunological agent
  DG02019  Interleukin inhibitor
   D10071  Ixekizumab
Drug classes [BR:br08332]
 Immunological agent
  DG02019  Interleukin inhibitor
   D10071  Ixekizumab
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokines
   Interleukins
    IL17A
     D10071  Ixekizumab (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D10071
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10071
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D10071
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D10071
Other DBs
CAS: 1143503-69-8
PubChem: 135626791
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system